Oncology Thought Leaders Assess Lead Compounds in Development for Ovarian Cancer

Share Article

New analysis from MedPredict sheds light on most important advances in treatment of ovarian cancer -- there continues to be significant unmet need for effective therapies, especially in metastatic disease.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat ovarian cancer.

Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15,000 women die each year in the US from ovarian cancer. While the 5-year survival for non-metastatic disease is 75%, only 20% of metastatic patients live this long. Thus there is an urgent unmet need for improved treatment strategies for ovarian cancer

This report, entitled “Thought Leader Insight & Analysis – Ovarian Cancer,” summarizes the perspectives of highly regarded U.S. based ovarian cancer specialists. In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics.

“The “next big thing” will be Avastin, so our panel evaluates inhibitors of PARP and mTOR/PI3K/AKT (& MEK) in a world where oncologists have moved from platinum doublets to a triplet containing bevacizumab, carboplatin and paclitaxel/gemcitabine/doxorubicin,” according to Jeff Berk, the report’s lead author. “The panel identifies strengths and weaknesses for lead compounds amongst the most important mechanisms in development for ovarian cancer.”

The report provides analysis of the following types of mechanisms/targets being studied:

  •     VEGF/PDGF/FGF/vascular disrupting agents
  •     DLL4/Notch
  •     EGFR
  •     alpha-folate receptor inhibitors
  •     Hedgehog
  •     IGF1R
  •     Immunologic approaches
  •     mTOR/PI3K/AKT MEK
  •     miRNA/siRNA
  •     PARP
  •     Platinums
  •     Superoxide
  •     Src, and
  •     Taxane/Epothilone.

Companies and partnerships mentioned in this report include: Abbott, Abraxis, Amgen, AstraZeneca, Bayer Healthcare/Onyx, Boehringer Ingelheim, Bristol-Myers Squibb, Cell Therapeutics, Endocyte, Genentech, GlaxoSmithKline, Infinity, Ortho Biotech (Johnson & Johnson), Keryx, Menarini, Morphotek/Eisai, OSI Pharmaceuticals/Genentech, OxiGene, Novartis, Pfizer, and Sanofi-Aventis.

This report can be purchased by contacting MedPredict at (513) 271-1924.

About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
MedPredict
(513) 271-1924
Email >
Visit website